References
- Adam ML, Pini C, Tulio S, Cantalice JCLL, Torres RA, Correia MTDS. 2015. Assessment of the association between micronuclei and the degree of uterine lesions and viral load in women with human papillomavirus. Cancer Genom-Proteom. 12:67–71.
- Ambroise MM, Balasundaram K, Phansalkar M. 2013. predictive value of micronucleus count in cervical intraepithelial neoplasia and carcinoma. Turk J Pathol. 29:171–178.
- Ault KA. 2006. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol. (2006:40470.
- Bodner-Adler B, Kimberger O, Schneidinger C, Koelbl H, Bodner K. 2016. Prognostic significance of pre-treatment serum c-reactive protein level in patients with adenocarcinoma of the uterine cervix. Anticancer Res. 36:4691–4696.
- Cassel APR, Barcellos RB, Silva CMDD, Almeida SE, d M, Rossetti MLR. 2014. Association between human papillomavirus (HPV) DNA and micronuclei in normal cervical cytology. Genet Mol Biol. 37:360–363.
- Cheng S, Schmidt-Grimminger D-C, Murant T, Broker TR, Chow LT. 1995. Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev. 9:2335–2349.
- Cortés-Gutiérrez E, Dávila-Rodríguez M, Vargas-Villarreal J, Hernández-Garza F, Cerda-Flores R. 2010. Association between human papilloma virus-type infections with micronuclei frequencies. Prague Med Rep. 111:35–41.
- Crook T, Vousden KH, Tidy JA. 1991. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell. 67:547–556.
- De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 7:453–459.
- Duensing S, Münger K. 2004. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer. 109:157–162.
- Dursun P, Senger SS, Arslan H, Kuşçu E, Ayhan A. 2009. Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit. BMC Infect Dis. 9:191–197.
- Ferlay J (2001). GLOBOCAN 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC Cancerbase.
- Gašperov NM, Sabol I, Matovina M, Spaventi Š, Grce M. 2008. Detection and typing of human papillomaviruses combining different methods: polymerase chain reaction, restriction fragment length polymorphism, line probe assay and sequencing. Pathol Oncol Res. 14:355–363.
- Gill G. 2012. Cytopreparation: principles and practice. New York: Springer Science and Business Media. Vol. 12 p. 143–189.
- He X, Li J-P, Liu X-H, Zhang J-P, Zeng Q-Y, Chen H, Chen S-L. 2018. Prognostic value of C-reactive protein/albumin ratio in predicting overall survival of Chinese cervical cancer patients overall survival: comparison among various inflammation based factors. J Cancer. 9:1877–1884.
- Hidalgo J, Rocher A, López J, Gamboni M, Vighi S, Canessa OE, Perssini S, Guerra F, Di Carlo MB, Palaoro L. 2012. AgNOR, p16 and human papillomavirus in low-grade squamous intra-epithelial lesions of the uterine cervix. Preliminary report. Biotech Histochem. 87:257–264.
- Hoory T, Monie A, Gravitt P, Wu T-C. 2008. Molecular epidemiology of human papillomavirus. J Formosan Med Assoc. 107:198–217.
- Inal M, Köse Ş, Yildirim Y, Özdemir Y, Töz E, Ertopçu K, Özelmas İ, Tinar Ş. 2007. The relationship between human papillomavirus infection and cervical intraepithelial neoplasia in Turkish women. Int J Gynecol Cancer. 17:1266–1270.
- Johnson-Obaseki S, Caulley L, Corsten M, Liu G, Dimitroulakos J, Goldstein D, Irish J, Rider J. 2019. C-reactive protein in HPV-positive and HPV-negative oropharyngeal cancer. Otolaryngol Head Neck Surg. 160:494–501.
- Lehucher-Michel M, Amara-Mokrane YA, Devictor B, Catilina P, Botta A. 1996. Micronuclei kinetics of exfoliated urothelial cells. Muta Res Fund Mol Mech Mutagen. 354:1–7.
- Lindner LE. 1993. Improvements in the silver-staining technique for nucleolar organizer regions (AgNOR). J Histochem Cytochem. 41:439–445.
- McLaughlin-Drubin ME, Münger K. 2009. Oncogenic activities of human papillomaviruses. Virus Res. 143:195–208.
- Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108.
- Parkin DM, Bray F. 2006. The burden of HPV-related cancers. Vaccine. 24:S11–S25.
- Polterauer S, Grimm C, Seebacher V, Rahhal J, Tempfer C, Reinthaller A, Hefler L. 2010. The inflammation-based Glasgow Prognostic Score predicts survival in patients with cervical cancer. Int J Gynecol Cancer. 20:1052–1057.
- Polterauer S, Grimm C, Zeillinger R, Heinze G, Tempfer C, Reinthaller A, Hefler L. 2011. Association of C-reactive protein (CRP) gene polymorphisms, serum CRP levels and cervical cancer prognosis. Anticancer Res. 31:2259–2264.
- Schiffman M, Castle PE. 2003. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 127:930–934.
- Srivastava AN, Misra JS, Singh U, Khan M, Raza S. 2019. AgNOR pleomorphic count as a tumor marker in cervical carcinogenesis and feasibility of its introduction in cervical cancer screening programs to discriminate high-risk cases of squamous intraepithelial lesions of the cervix. Acta Cytol. 63:371–378.
- Trere D. 2000. AgNOR staining and quantification. Micron. 31:127–131.